NCT07104162View on ClinicalTrials.gov

A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

December 23, 2026

Conditions

Bacterial Infections

Interventions

DRUG

Cefiderocol/Xeruborbactam

A fixed dose combination of intravenous cefiderocol and intravenous xeruborbactam

Trial Locations (2)

32809

RECRUITING

Orlando Clinical Research Center, Orlando

33136

RECRUITING

University of Miami Clinical Pharmacology, Miami

All Listed Sponsors

collaborator

Shionogi Inc.

INDUSTRY

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Qpex Biopharma, Inc.

INDUSTRY

NCT07104162 - A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment | Biotech Hunter | Biotech Hunter